EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy

Takako Inoue, Takehisa Watanabe, Yasuhito Tanaka

Clinical and Molecular Hepatology · 2023

DOI: 10.3350/cmh.2022.0434 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2023. Verfasst von Takako Inoue und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic, Hepatitis B. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Fujirebio, Inc., Sysmex Corporation, Gilead Sciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current requirement for biomarkers to detect hepatitis B virus (HBV) infection is polarized. One is a fully-automated and highly sensitive measurement system; the other is a simple system for point-of-care testing (POCT) in resource-limited areas. Hepatitis B core-related antigen (HBcrAg) reflects intrahepatic covalently closed circular DNA and serum HBV DNA. Even in patients with undetectable serum HBV DNA or HBsAg loss, HBcrAg may remain detectable. Decreased HBcrAg levels are associated with reduction of the occurrence of hepatocellular carcinoma (HCC) in chronic hepatitis B. Recently, a fully-automated, novel high-sensitivity HBcrAg assay (iTACT-HBcrAg, cut-off value: 2.1 logIU/mL) has been developed. This attractive assay has been released in Japan very recently. iTACT-HBcrAg can be useful for monitoring HBV reactivation and prediction of HCC occurrence, as an alternative to HBV DNA. Moreover, monitoring HBcrAg may be suitable for determining the therapeutic effectiveness of approved drugs and novel drugs under development. Presently, international guidelines recommend anti-HBV prophylaxis for pregnant women with high viral loads to prevent mother-to-child transmission of HBV. However, >95% of HBV-infected individuals live in countries where HBV DNA quantification is not available. Worldwide elimination of HBV needs the scaling-up of examination and medication services in resource-limited areas. Based on this situation, a rapid and easy HBcrAg assay as a POCT is valuable. This review provides the latest information regarding the clinical use of a new surrogate marker, HBcrAg, in HBV management, based on iTACT-HBcrAg or POCT, and introduces novel agents targeting HBV RNA/protein.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B, ChronicHepatitis BPregnancyFemaleHumansHepatitis B virusHepatitis B Core AntigensDNA, ViralInfectious Disease Transmission, VerticalBiomarkersHepatitis B Surface Antigens

Stichwörter der Autor:innen

Covalently closed circular DNA (cccDNA)HBV reactivationHepatitis B core-related antigen (HBcrAg)Point-of-care testingRNA destabilizer

Substanzen

Hepatitis B Core AntigensDNA, ViralBiomarkersHepatitis B Surface Antigens

Autor:innen und Institutionen

  • Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya, Japan.
  • Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Virology & Liver unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Förderung

  • Fujirebio, Inc.
  • Sysmex Corporation
  • Gilead Sciences, Inc.
  • Janssen Pharmaceutical K.K.
  • GlaxoSmithKline PLC.

Zitieren

APA

Inoue, T., Watanabe, T., & Tanaka, Y. (2023). Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2022.0434

Vancouver

Inoue T, Watanabe T, Tanaka Y. Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy. Clinical and Molecular Hepatology. 2023. doi:10.3350/cmh.2022.0434

BibTeX
@article{Inoue2023,
  author = {Inoue, Takako and Watanabe, Takehisa and Tanaka, Yasuhito},
  title = {Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy},
  journal = {Clinical and Molecular Hepatology},
  year = {2023},
  doi = {10.3350/cmh.2022.0434}
}
Kostenlos starten →